Gauthier et al, 2023.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Nature Biotechnology
Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology
Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by...
Claire de SAINT BLANQUAT
Vice President, Legal and Corporate Affairs and Secretary of the Supervisory Board
Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Sanofi gains exclusive license to Innate’s B7H3 ANKET TM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022
Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKET TM (Antibody...
Number of shares and voting rights of Innate Pharma as of December 1, 2022
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical data...
Innate Pharma Reports Third Quarter Financial Results
Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab...
Innate Pharma announces conference call and webcast for third quarter 2022 business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET / 8 a.m...
Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022
Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric Vivier...